All News
SPACING trial OP0138 at #EULAR2021
⭐️RCT by the French showing non-inferiority of spacing TNFi in r-axSpA pts w/ LDA (BASDAI<4 x 6mo)
⭐️ 88% in spacing group remained w/ LDA vs 91.5% in standard tx
⭐️ADA, CTZ, GOL, IFX spaced by 1w intervals. ETN by 3-4d & 1w. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR Presentation 3478: Infection risk with surgeries:
⭐️Continue conventional DMARD
⭐️Some risk with biologics, may be confounder and no association with timing of infusions
⭐️Steroids are major risk factor! Esp >10 mg/d
⭐️Recommendations shown
⭐️Address other risks!
@rheumnow https://t.co/Bi02d4p9Mw
Eric Dein ejdein1 ( View Tweet)
Abst#OP0137 at #EULAR2021:
➡️TNFi use for at least 1 year decreased radiographic sacroiliitis progression in early AxSpA in this ten year multicenter study of the German Spondyloarthritis Inception cohort (GESPIC) .
➡️This effect becomes evident 2-4 years after tx.
@RheumNow https://t.co/GNnYqYmxhl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
COAST-V: IXE ⬇️SP-N & spinal pain in r-axSpA pts w/ or w/o ⬆️ CRP or morning stiffness. Pts treated w/ ADA re-randomized to IXE showed further⬇️in SP-N & spinal pain. Poster #POS0901 #EULAR2021 @RheumNow https://t.co/46qiqrohbX https://t.co/uB15oTwztV
Dr. Rachel Tate uptoTate ( View Tweet)
#OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead!
@RheumNow https://t.co/E61yb97CRN
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021: Do you start a bDMARD for nr-AxSpa without objective evidence of inflammation (elevated CRP, negative structural damage on MRI)? @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006
Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO
Paul Studenic Stiddyo ( View Tweet)
Can we taper IV belimumab in #SLE? Dr Fredi reported 14/48 (29%) extended tx to at least 5-weekly after 12mo of tx. No worsening C3/C4 & PGA but interestingly #steroid and SLEDAI ⬇️. More works needed to identify suitable pts for taper and regime #EULAR2021 #POS0107 @RheumNow https://t.co/Gwe7mPWPdY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Do look out for Abst #OP0057 today 2/6/21 1645 CEST #EULAR2021. We propose a data-driven algorithm for #rituximab maintenance in #ANCA #vasculitis to avoid excessive retreatment and low IgG @RheumJArn @edvital P. Emery @LeedsMedHealth @LTHTResearch @LeedsHospitals @LeedsBRC https://t.co/XRR0NFnpMu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
🚨So after LoVAS
Now this
Ritux + MMF + Pulse MPS
No oral steroids 🤯
@ARD_BMJ
@EBRheum - Lesser is better ??
https://t.co/CYMNX8wLtd https://t.co/NtwTas3ZdS
EnvisionRheumat ERheumat ( View Tweet)
Positive RCT of Rituximab in Systemic sclerosis https://t.co/WsDZeollu0
Richard Conway RichardPAConway ( View Tweet)
Dr Atienza-Mateo presents on IFX ADA TCZ in Behcets refractory uveitic cystoid macular oedema. All appear effective! @RheumNow #EULAR2021 Abstr#OP0060 https://t.co/Vpju0IvrC5
Richard Conway RichardPAConway ( View Tweet)
Dr Mekinian presents data showing TCZ and TNFi appear equally effective in TAK, complete response 66% vs 70% at 6 months @RheumNow #EULAR2021 Abstr#OP0068
Richard Conway RichardPAConway ( View Tweet)
Dr Sanchez-Bilbao presents surprising data that tocilizumab may improve even permanent vision loss in GCA @RheumNow #EULAR2021 Abstr#OP0065 https://t.co/oFGNZ04oKr
Richard Conway RichardPAConway ( View Tweet)
Dr Arnold @Yuz6Yusof present on personalised rituximab retreatment in AAV. Interesting that naive B-cell repopulation at 6 months predicts better sustained response compared to absence @RheumNow #EULAR2021 Abstr#OP0057 https://t.co/cypyQVMeYz
Richard Conway RichardPAConway ( View Tweet)
@jeffsparks knocking it out of the park presenting our findings on b/tsDMARD associations with COVID-19 outcomes @eular_org @EULAR_Press check out our full paper just published in @ARD_BMJ https://t.co/jcA1LN45R3
Zach Wallace zach_wallace_md ( View Tweet)
Secukinumab effective in AS patients, irrespective of gender
AQUILA 52 week study
⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women
⭐️women had overall higher disease burden in global functioning and depressive mood
POS0899
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Atienza-Mateo presents abstract #POS0595 on abatacept in RA-ILD. Abatacept surprisingly appeared to be equally good in stabilising FVC and DLCO in both UIP and NSIP patterns in RA-ILD. @RheumNow #EULAR2021 Abstr#POS0595 https://t.co/kHUxWXnaBG
Richard Conway RichardPAConway ( View Tweet)
C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA
⭐️82% ⬇️ in uveitis flare event
⭐️reduction in axSpA disease activity
⭐️no new safety signals
POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY
Robert B Chao, MD doctorRBC ( View Tweet)
